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Rheumatoid arthritis (RA) is a common systemic disease that manifests as inflammatory arthritis of multiple joints and produces a wide
variety of intrathoracic lesions, including pleural diseases, diffuse interstitial pneumonia, rheumatoid nodules, and airway disease. Patients
treated for RA can have associated lung disease that commonly manifests as diffuse interstitial pneumonia, drug-induced lung injury, and
infection. The purpose of this pictorial review is to illustrate the radiographic and clinical features of lung complications of acute or subacute
onset in patients treated for RA and to show the computed tomography features of these complications.Resume
La polyarthrite rhumato€ıde est une maladie systemique commune qui se manifeste sous forme d’arthrite inflammatoire touchant de
multiples articulations et entra^ıne une grande variete de lesions intrathoraciques, dont des maladies pleurales, la pneumonie interstitielle
diffuse, des nodules rhumato€ıdes et des maladies des voies respiratoires. Les patients qui rec¸oivent un traitement contre la polyarthrite
rhumato€ıde peuvent souffrir d’atteintes pulmonaires associees qui se manifestent communement sous forme de pneumonie interstitielle, de
lesions pulmonaires d’origine medicamenteuse et d’infections. Cette revue iconographique vise a illustrer les aspects radiographiques et
cliniques des complications pulmonaires aigu€es et subaigu€es chez les patients qui suivent un traitement contre la polyarthrite rhumato€ıde,
ainsi qu’a demontrer les aspects tomodensitometriques de ces complications.
 2013 Canadian Association of Radiologists. All rights reserved.
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months) in patients treated for rheumatoid arthritis (RA) are
divided into 2 major categories: (1) lung complications of the
RA itself [1,2] and (2) those related to RA treatment, which
include drug-induced lung injury (DLI) and infection.
Because clinical and radiographic features of these lesions
are similar, the correct diagnosis requires understanding of
the combined features. In this article, we illustrate clinical
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Common acute or subacute lung complications of RA
include organizing pneumonia (OP) and acute exacerbation
(AE) of pre-existing chronic interstitial pneumonia (CIP).
Acute interstitial pneumonia (AIP) without pre-existing CIP
is rare in patients with RA.
OP
OP is one of the most frequent lung complications of RA.
Imaging features are multiple nonsegmental foci of consol-
idation, which show subpleural or peribronchovascular
distribution [3]. Ground-glass opacity (GGO) may be present
in the periphery of the consolidation. Traction bronchiectasis
may be identified within the consolidation. Differentialll rights reserved.
Figure 1. Organizing pneumonia (OP). A 66-year-old woman who under-
went salazosulfapyridine therapy for 2 years. High-resolution computed
tomography, showing multiple foci of consolidation (arrow) in the subpleural
regions. She did not recover completely after administration of broad-
spectrum antibiotic drugs, and a new lesion appeared in the right upper
lobe. We diagnosed OP based on clinical history and exclusion of infection.
Figure 3. Drug-induced lung injury, acute interstitial pneumonia (AIP)-like
pattern. Methotrexate (MTX)-induced lung injury (AIP-like pattern) in a 69-
year-old man with pre-existing chronic interstitial pneumonia (CIP) who had
been treated with MTX for 4 years. Computed tomography, showing bilat-
eral heterogeneous ground-glass opacity that overlaps pre-existing interstitial
pneumonia (IP) of usual (usual IP) pattern in the lower lobes. Traction
bronchiectasis (arrow) is evident, which suggests diffuse alveolar damage-
like pattern. Because this patient with CIP developed AE whose trigger
was thought to be MTX, we diagnosed MTX-induced lung injury.
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monia, and OP-like DLI (Figure 1 [OP]).
AE of CIP
AE of CIP may develop with RA; symptoms may rapidly
progress within 1 month. In patients with RA, AE of CIP
may occur with nonspecific interstitial pneumonia (NSIP)
but less frequently than AE of CIP with the usual IP (UIP)
pattern [2,4]. Imaging features of AE are diffuse or multiple
patchy areas of GGO that overlap the features of CIP.Figure 2. Acute exacerbation of chronic fibrosing interstitial pneumonia (IP). Chro
woman with dyspnea for 2 weeks who had undergone therapy with bucillamine an
(HRCT), showing patchy reticular opacity in the subpleural region before the onse
that overlaps pre-existing shadow at the onset of lung disease within 1 month. Her
at the onset of signs. A diagnosis of acute exacerbation of CIP was more likelyReticular opacity or honeycombing suggests fibrotic
changes. Traction bronchiectasis and structural distortion are
frequently seen as well. Comparison with previous images is
useful for differentiation, and the presence of honeycomb
lung suggests AE of CIP caused by AIP (Figure 2 [AE of
UIP in RA]).
Complications Related to RA Treatment
Common acute or subacute lung complications include
DLI and infection.nic IP (CIP) of the usual interstitial pattern (usual IP pattern) in a 73-year-old
d salazosulfapyridine for 6 years. (A) High-resolution computed tomography
t of acute exacerbation. (B) HRCT, showing widespread ground-glass opacity
rheumatoid arthritis was poorly controlled, and she did not change medicine
than drug-induced lung injury.
Figure 4. Drug-induced lung injury, organizing pneumonia (OP)-like pattern. Methotrexate (MTX)-induced lung injury (OP-like pattern) in a 73-year-old man
with a dry cough and fever who had been treated with MTX for 3 months. (A) Computed tomography (CT) and (B) high-resolution CT, showing multiple foci
of consolidation in the subpleural and peribronchovascular regions.
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antirheumatic drugs have been used to treat patients with
RA, low-dose methotrexate (MTX) is the recent standard
treatment [5]; use of anticytokine biologic drugs, such as
infliximab, etanercept, and tocilizumab, has also spread
rapidly. Because autoimmune mechanisms play an important
role in DLI, patients with RA seem more susceptible to DLI.Clinical Features of DLI
Clinical signs and symptoms of DLI are nonspecific
respiratory symptoms, such as dry cough and exertional
dyspnea. There are no reliable noninvasive laboratory tests
for diagnosing DLI. Accurate diagnosis requires integration
of clinical, imaging, and laboratory findings, and includes
observation of the temporal relationship between onset of
signs and administration of suspicious drugs, the exclusion of
infection, and the progression of complications of RA itself.
One of the most important roles of imaging diagnosis in the
evaluation of DLI is the detection of pre-existing CIP andFigure 5. Drug-induced lung injury, nonspecific interstitial pneumonia (NSIP)-lik
old man with dyspnea who had been treated with bucillamine for 2 months. (A) C
of ground-glass opacity along the bronchovascular bundles that mimic NSIP.other destructive diseases, which constitute one of the most
important risk factors of DLI.Imaging Features of DLI
Fundamental imaging features of DLI are patchy or
diffuse GGO and/or consolidation that is occasionally
accompanied by reticular opacity and interlobular septal
thickening. Images of DLI have been classified by similari-
ties to idiopathic forms of lung injury. Based on imaging
features, patterns of DLI are classified as AIP-like, OP-like,
hypersensitivity pneumonia (HP)-like, eosinophilic
pneumonia-like, or NSIP- like pattern, or as unclassifiable
[6]. However, because pathologic findings have not been
fully evaluated, the application of such imaging classification
of DLI is limited. Although DLI caused by a particular drug
frequently demonstrates a specific pattern, DLI caused by
a single drug may manifest with different pathologic and/or
imaging patterns. On computed tomography (CT), the most
frequent pattern of MTX-induced DLI is an HP-like pattern;
diffuse or widespread patchy GGO that corresponds to
pathologic findings of lymphocytic infiltration, with smalle pattern. Bucillamine-induced lung injury (NSIP-like pattern) in a 74-year-
omputed tomography (CT) and (B) high-resolution CT, showing multiple foci
Figure 6. Drug-induced lung injury (DLI), hypersensitivity pneumonia (HP)-
like pattern. Methotrexate (MTX)-induced lung injury (HP-like pattern) in
a 67-year-old woman with dyspnea who had been treated with MTX for 1
month. High-resolution computed tomography, showing diffuse ground-glass
opacity, without structural distortion. The patients discussed in Figures 4e6
changed medications just before the onset of signs. These patients should be
considered as DLI after exclusion of infection.
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MTX-induced malignant lymphoma may also show acute or
subacute onset with generalized symptoms, such as fever
(Figure 3 [DLI AIP-like]; Figure 4 [DLI OP-like]; Figure 5
[DLI NSIP-like]; Figure 6 [DLI HP-like MTX]; Figure 7
[MTX-induced malignant lymphoma]).InfectionThe combination of MTX and anticytokine biologic drugs
has become a standard therapeutic regimen for RA, but itFigure 7. Methotrexate (MTX)-induced malignant lymphoma. MTX-induced mali
with MTX for several years. (A) Computed tomography (CT) and (B, C) high
bronchovascular distribution. Figure courtesy of M. Ishida, MD, Department of Cinduces immunodeficiency that may cause opportunistic
infection, one of the most serious and frequent complica-
tions. In patients with RA, bacterial pneumonia is the most
frequent infection, but tuberculosis, fungal infection, Pneu-
mocystis jiroveci pneumonia (PcP), and other pneumonia
may occur as opportunistic infections. The criterion standard
for diagnosing infection is the bacteriologic and/or serologic
identification of causative organisms, but other auxiliary tests
may be useful.
Bacterial Infection
Bacterial pneumonia is the most frequent infection in
patients treated for RA and may be diagnosed with the tests
for urine antigens of Streptococcus pneumonia and Legion-
ella pneumophila. Imaging features of bacterial pneumonia
include consolidation from lobular size to lobar distribution
(Figure 8 [bacterial pneumonia]).
Mycobacterial Infection
Recently, the wide use of anticytokine biologic drugs has
increased the risk of tuberculosis in patients with RA.
Prophylactic administration of antituberculous drugs is
recommended in patients at high risk for tuberculosis, such
as those with pre-existing tuberculosis or diabetes mellitus or
those who have undergone glucocorticoid treatment. Stan-
dard tests to identify Mycobacterium tuberculosis include
acid-fast bacillus staining and/or polymerase chain reaction
(PCR) for sputum or gastric juice. QuantiFERON (Cellestis
Limited, Carnegie, Victoria, Australia) is a more sensitive
and specific test to diagnose tuberculosis that can detect
Mycobacterium tuberculosis infection more accurately than
the tuberculin purified protein derivative skin test [8,9].
Imaging features of postprimary tuberculosis include
a small, well-circumscribed, nodular opacity approximately
5e10 mm in diameter that typically shows centrilobular
distribution. Large cavitary nodule and/or mass shadow or
consolidation may be seen. Miliary tuberculosis involves the
hematogenous spread of tuberculosis bacilli and appears asgnant lymphoma in a 54-year-old man with fever and cough who was treated
-resolution CT, showing multiple nodular and/or mass opacities, with peri-
linical Medicine, Institute of Tropical Medicine, Nagasaki University, Japan.
Figure 8. Bacterial pneumonia. Bacterial pneumonia in a 65-year-old woman with fever, cough, and sputum who had received steroid treatment for 1 year. (A)
Chest radiograph and (B) computed tomography, showing unilateral and segmental focus of consolidation (arrows). Diagnosis of bacterial pneumonia is based
on positive urine Streptococcus pneumoniae antigen.
Figure 9. Tuberculosis. Pulmonary tuberculosis in a patient with rheumatoid arthritis treated with tumour necrosis factor inhibitors (infliximab) and metho-
trexate. (A) Chest radiograph, showing consolidation in bilateral lobes (arrows). (B) High-resolution computed tomography, showing centrilobular foci
consolidation (arrow), nodules, and branching opacity (tree-in-bud appearance [arrowhead]) in the left upper lobe. Mycobacterium tuberculosis was identified
from sputum.
Figure 10. Miliary tuberculosis. Miliary tuberculosis in a 65-year-old woman with cough who had been treated with tocilizumab for 2 years. (A) Chest
radiograph and (B) high-resolution computed tomography, showing multiple miliary nodules with random distribution. Diagnosis of miliary tuberculosis is
based on bacteriologic detection of Mycobacterium tuberculosis from sputum and gastric juice.
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Figure 11. Cryptococcosis. Cryptococcosis in a 71-year-old woman with cough who had been treated with bucillamine for 2 years. (A) Computed tomography
(CT) and (B) high-resolution CT, showing multiple subpleural nodules and/or consolidation in the lower lobes that mimic cryptogenic organizing pneumonia.
The patient’s symptoms and radiologic abnormalities resolved after institution of fluconazole therapy.
Figure 12. Chronic necrotizing aspergillosis. Chronic necrotizing aspergil-
losis in a 62-year-old man who had received steroid treatment.
High-resolution computed tomography, showing a large cavity lesion that
contained a fungus ball in the left upper lobe. Aspergillus fumigatus was
identified from sputum.
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diameter (Figure 9 [tuberculosis]; Figure 10 [miliary tuber-
culosis]). In patients with RA, airway injury and decreased
immunity from treatment may cause vulnerability to non-
tuberculous mycobacteriosis. Imaging features may mimic
tuberculosis or present nodular or patchy consolidation
predominantly in the right middle lobe and left lingula.
Administration of anticytokine biologic drugs may be
restricted in cases with nontuberculous mycobacteriosis [10].
Fungal Infection
Fungal infection, such as Aspergillus and Cryptococcus
neoformans, is also seen in patients with RA. Invasive
aspergillosis is rare in patients with RA. Structural distortion
and decreased immunity from RA may increase the risk of
chronic necrotizing aspergillosis (Figure 11 [cryptococcosis];
Figure 12 [chronic necrotizing aspergillosis]).
PcP
One of the most common infections in patients with RA is
PcP. The criterion standard for its diagnosis is appropriate
staining to identify the organism in respiratory tract secre-
tion. In most PcP in patients treated for RA, sputum shows
positive PCR with negative staining of P jiroveci. Serum b-D
glucan is a useful auxiliary test for PcP; with a cut-off level
estimated at 31.1 pg/mL, sensitivity of 92%, and specificity
of 86% [11]. Imaging features of PcP include GGO without
structural distortion. GGO may show panlobular or multi-
lobular distribution with sharp demarcation [12] (Figure 13
[PcP]).
Diagnosis Pitfall
In patients treated for RA, radiographic features of lung
complications of acute or subacute onset often overlap.
Especially, diffuse GGO is frequently seen in many diseases.
Correct differential diagnosis requires knowledge of andattention to clinical and imaging features and exclusion of
infection with laboratory tests (Figures 14e16).
Conclusion
Although lung complications of acute or subacute onset in
patients with RA are often difficult to diagnose, knowledge
of their combined clinical signs and course, as well as
laboratory and radiologic findings, is an important tool in
assessing these patients.
Figure 13. Pneumocystis jiroveci pneumonia (PcP). Presumptive PcP in a 74-year-old woman with dyspnea and cough who was treated with a tumour necrosis
factor inhibitor (infliximab) for 1 month. (A) Chest radiograph and (B) computed tomography, showing bilateral patchy ground-glass opacity with peripheral
sparing. Serum b-D glucan >31.1 pg/mL, bronchoalveolar lavage: positive Pneumocystis polymerase chain reaction.
Figure 14. A 65-year-old man with pre-existing chronic interstitial pneumonia (IP) of usual pattern who had been treated with bucillamine for 3 years. (A, B)
Computed tomography at onset, showing widespread patchy ground-glass opacity and peripheral sparing. Laboratory data: white blood cell count, 11090/mL
(neutrophils, 92.2%); C-reactive protein, 7.99 mg/dL; KL-6, 1880 U/mL; serum b-D glucan, 112 pg/mL. Bronchoalveolar lavage (BAL): positive Pneumocystis
polymerase chain reaction (PCR), negative Groccot stain of sputum. Diagnosis of Pneumocystis jiroveci pneumonia was based on increased serum b-D glucan
and positive Pneumocystis PCR on BAL.
Figure 15. An 87-year-old man with dyspnea who was treated with bucillamine for 2 year. (A) Computed tomography (CT) findings at onset, showing diffuse,
patchy ground-glass opacity (GGO) and reticular opacity in the lower lobes. (B) CT findings before onset show patchy reticular opacity in the subpleural
region. Laboratory data: KL-6, 2058 U/L; surfactant protein-D, 415.7 ng/mL; Serum b-D glucan, 13.8 pg/mL. Bronchoalveolar lavage: negative Grocott stain;
negative Pneumocystis polymerase chain reaction. First, we suspected bucillamine-induced lung injury. However, her symptoms and CT abnormalities did not
improve despite cessation of bucillamine, so we thought acute exacerbation of usual (usual interstitial pneumonia) pattern was more likely than drug-induced
lung injury.
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Figure 16. A 75-year-old man with no lung disease who had been treated with methotrexate (MTX) for 4 years. (A) Computed tomography (CT), showing
bilateral heterogeneous ground-glass opacity (GGO) and traction bronchiectasis in the lower lobes. (B) High-resolution CT, showing diffuse thickening of the
interlobular septa and a scattered area of GGO. Laboratory data: white blood cell count, 19220/mL; (neutrophils: 91.4%); C-reactive protein, 16 mg/dL; KL-6,
1880 U/mL; Serum b-D glucan, <6.0 pg/mL. Bronchoalveolar lavage: negative Pneumocystis polymerase chain reaction, and bacteria. Diagnosis of acute
drug-induced lung injury caused by MTX was based on exclusion of acute interstitial pneumonia, with no pre-existing chronic interstitial pneumonia; such
a diagnosis is rare in patients with rheumatoid arthritis.
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